However, while the potential association between prolactin-elevating antipsychotics and breast cancer survival requires further exploration these results when restricting to patients with similar diagnoses should provide some reassurance for clinicians around the use of antipsychotics in breast cancer patients, in whom psychiatric disorders are often undertreated [19]. The gene discussed is PRL; the disease is breast carcinoma.